Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEVAX and REVAXIS in adults >40y without recent booster
NCT01287949Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2011
- Primary completion
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Adacel Polio and Revaxis in diphtheria, Tetanus, pertussis and 1 more, sponsored by Sanofi. Primary endpoints: Diphtheria seroprotection rate, Tetanus seroprotection rate and 2 more. Started Jan 2011; status: completed.
02
Drugs
Adacel PolioRevaxis
03
Conditions
diphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT01287949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287949.